دورية أكاديمية
Development of Immunotherapy Combination Strategies in Cancer.
| العنوان: | Development of Immunotherapy Combination Strategies in Cancer. |
|---|---|
| المؤلفون: | Yap TA; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. tyap@mdanderson.org.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parkes EE; Oxford Institute of Radiation Oncology, University of Oxford, Oxford, United Kingdom., Peng W; Department of Biology and Biochemistry, University of Houston, Houston, Texas., Moyers JT; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Curran MA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| المصدر: | Cancer discovery [Cancer Discov] 2021 Jun; Vol. 11 (6), pp. 1368-1397. Date of Electronic Publication: 2021 Apr 02. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research |
| مواضيع طبية MeSH: | Immune Checkpoint Inhibitors/*therapeutic use , Neoplasms/*drug therapy, Drug Development ; Drug Therapy, Combination ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immunotherapy |
| مستخلص: | Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has revolutionized the landscape of cancer. Rational combination strategies aim to enhance the antitumor effects of immunotherapies, but require a deep understanding of the mechanistic underpinnings of the immune system and robust preclinical and clinical drug development strategies. We review the current approved immunotherapy combinations, before discussing promising combinatorial approaches in clinical trials and detailing innovative preclinical model systems being used to develop rational combinations. We also discuss the promise of high-order immunotherapy combinations, as well as novel biomarker and combinatorial trial strategies. SIGNIFICANCE: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. Innovative approaches are required to guide the development of novel immunotherapy combinations, ranging from improvements in preclinical tumor model systems to biomarker-driven trial strategies. (©2021 American Association for Cancer Research.) |
| References: | N Engl J Med. 2018 Jun 14;378(24):2288-2301. (PMID: 29863955) Sci Transl Med. 2015 Apr 15;7(283):283ra52. (PMID: 25877890) J Gene Med. 2012 Jun;14(6):405-15. (PMID: 22262649) Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290) J Immunol. 1995 May 1;154(9):4685-92. (PMID: 7722321) Cancer Immunol Res. 2015 Apr;3(4):399-411. (PMID: 25678581) N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881) Front Oncol. 2019 Mar 19;9:156. (PMID: 30941308) Nat Immunol. 2009 Jan;10(1):29-37. (PMID: 19043418) N Engl J Med. 2018 Nov 29;379(22):2108-2121. (PMID: 30345906) Cancer. 2019 Dec 1;125(23):4193-4202. (PMID: 31398264) Science. 2011 Mar 25;331(6024):1612-6. (PMID: 21436454) J Immunol. 1979 Feb;122(2):549-54. (PMID: 310843) Blood. 2005 Nov 1;106(9):3127-33. (PMID: 16037385) Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. (PMID: 28698201) J Exp Med. 2006 Nov 27;203(12):2691-702. (PMID: 17101732) N Engl J Med. 2013 Apr 4;368(14):1365-6. (PMID: 23550685) JCI Insight. 2018 Oct 18;3(20):. (PMID: 30333318) Nat Biotechnol. 2014 Apr;32(4):364-72. (PMID: 24633240) J Clin Invest. 2018 Nov 1;128(11):5137-5149. (PMID: 30188869) Clin Cancer Res. 2016 Sep 15;22(18):4585-93. (PMID: 27225694) JAMA Oncol. 2020 May 1;6(5):676-684. (PMID: 32053137) N Engl J Med. 2019 Aug 15;381(7):626-636. (PMID: 31166680) Lancet. 2020 Jun 13;395(10240):1835-1844. (PMID: 32534646) Oncoimmunology. 2019 Apr 12;8(7):1596005. (PMID: 31143518) Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084) Ann Oncol. 2019 Feb 1;30(2):219-235. (PMID: 30608567) Cell Rep. 2019 Apr 16;27(3):806-819.e5. (PMID: 30995478) Carcinogenesis. 2000 Apr;21(4):585-91. (PMID: 10753190) Nat Rev Cancer. 2015 Aug;15(8):457-72. (PMID: 26205340) Sci Transl Med. 2017 Oct 4;9(410):. (PMID: 28978752) Lancet Respir Med. 2019 May;7(5):387-401. (PMID: 30922878) Oncoimmunology. 2015 Aug 17;5(7):e1052212. (PMID: 27622011) Sci Transl Med. 2017 Apr 12;9(385):. (PMID: 28404866) N Engl J Med. 2020 Jan 2;382(1):60-72. (PMID: 31893516) Ann N Y Acad Sci. 2019 Jun;1445(1):62-73. (PMID: 30945313) Clin Cancer Res. 2019 Jun 1;25(11):3210-3219. (PMID: 30670489) Ann Oncol. 2014 Aug;25(8):1544-50. (PMID: 24608200) J Exp Med. 2019 May 6;216(5):1199-1213. (PMID: 30936263) N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635) Sci Transl Med. 2018 Jan 3;10(422):. (PMID: 29298865) Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526) Cancer Res. 2012 Oct 15;72(20):5209-18. (PMID: 22915761) Blood. 2018 Apr 5;131(14):1617-1621. (PMID: 29439955) Immunity. 2014 Nov 20;41(5):843-52. (PMID: 25517616) J Hematol Oncol. 2017 Sep 20;10(1):155. (PMID: 28931402) Neuro Oncol. 2018 Jan 22;20(2):225-235. (PMID: 29016938) Nature. 2016 Nov 17;539(7629):443-447. (PMID: 27828943) Clin Cancer Res. 2017 Jan 15;23(2):454-465. (PMID: 27470968) Clin Cancer Res. 2019 Mar 1;25(5):1462-1471. (PMID: 30377198) Cancer Cell. 2011 Jun 14;19(6):754-64. (PMID: 21665149) J Thorac Oncol. 2018 Sep;13(9):1393-1399. (PMID: 29775808) Cancer Immunol Res. 2016 Nov;4(11):936-947. (PMID: 27680026) J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32238470) Oncoimmunology. 2016 Dec 23;6(1):e1261779. (PMID: 28197389) Immunity. 2004 Oct;21(4):503-13. (PMID: 15485628) Vet Pathol. 2012 Jan;49(1):32-43. (PMID: 22135019) Lancet. 2019 Jun 15;393(10189):2404-2415. (PMID: 31079938) Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. (PMID: 20160101) J Thorac Oncol. 2020 Feb;15(2):288-293. (PMID: 31622733) J Immunother Cancer. 2018 Jun 18;6(1):57. (PMID: 29914571) J Immunother Cancer. 2018 Jun 21;6(1):59. (PMID: 29925431) Genes Dev. 2017 Feb 15;31(4):353-369. (PMID: 28279982) Cancer Res. 2012 Jul 1;72(13):3163-74. (PMID: 22570253) J Immunother Cancer. 2018 Dec 4;6(1):141. (PMID: 30514390) Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. (PMID: 27756788) J Immunol. 1989 Feb 15;142(4):1366-71. (PMID: 2464645) Lancet Oncol. 2020 Jan;21(1):44-59. (PMID: 31786121) N Engl J Med. 2019 Mar 21;380(12):1116-1127. (PMID: 30779529) J Natl Cancer Inst. 2016 Oct 5;109(1):. (PMID: 27707838) MAbs. 2016;8(3):593-603. (PMID: 26918260) Immunity. 2015 Feb 17;42(2):332-343. (PMID: 25692705) J Hematol Oncol. 2018 Aug 2;11(1):100. (PMID: 30068361) Cancer Immunol Res. 2019 Mar;7(3):443-457. (PMID: 30651291) J Clin Oncol. 2020 Sep 10;38(26):2981-2992. (PMID: 32167863) N Engl J Med. 2019 Apr 11;380(15):1450-1462. (PMID: 30970190) Nature. 2018 Aug;560(7718):382-386. (PMID: 30089911) Ann Oncol. 2020 Aug;31(8):1030-1039. (PMID: 32339648) Nat Med. 2018 Dec;24(12):1845-1851. (PMID: 30397353) Ann Oncol. 2019 Mar 1;30(3):397-404. (PMID: 30475950) Sci Transl Med. 2018 Jan 31;10(426):. (PMID: 29386357) Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383) Clin Cancer Res. 2020 Sep 15;26(18):4842-4851. (PMID: 32586938) Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.4. (PMID: 18432777) Cell. 2015 Apr 9;161(2):205-14. (PMID: 25860605) N Engl J Med. 2018 Apr 05;378(14):1277-1290. (PMID: 29562145) Nature. 2016 Nov 17;539(7629):437-442. (PMID: 27642729) Cancer Res. 1973 Aug;33(8):1837-44. (PMID: 4720795) Cancer Discov. 2019 Mar;9(3):370-383. (PMID: 30409776) JAMA Oncol. 2020 Mar 1;6(3):375-384. (PMID: 31876895) Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990. (PMID: 29203668) Cancer Discov. 2019 May;9(5):646-661. (PMID: 30777870) Lancet Oncol. 2019 Aug;20(8):1083-1097. (PMID: 31221619) Clin Cancer Res. 2015 Dec 15;21(24):5543-51. (PMID: 26187615) Nat Commun. 2017 Jun 09;8:15618. (PMID: 28598415) Lancet Oncol. 2015 Aug;16(8):908-18. (PMID: 26115796) J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550) Mol Med Rep. 2018 May;17(5):7045-7054. (PMID: 29568923) Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945) J Immunother Cancer. 2019 Feb 8;7(1):37. (PMID: 30736857) Immunity. 2013 Apr 18;38(4):729-41. (PMID: 23562161) Clin Cancer Res. 2018 Dec 1;24(23):5792-5806. (PMID: 29945993) J Clin Oncol. 2019 Apr 10;37(11):867-875. (PMID: 30811280) J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075) Lancet Oncol. 2019 Feb;20(2):239-253. (PMID: 30660609) N Engl J Med. 2015 May 21;372(21):2006-17. (PMID: 25891304) Lancet Oncol. 2017 May;18(5):611-622. (PMID: 28359784) J Natl Cancer Inst. 1979 Apr;62(4):1017-23. (PMID: 107359) Nat Med. 2020 Apr;26(4):566-576. (PMID: 32251400) Nat Med. 2018 Sep;24(9):1441-1448. (PMID: 30082870) Clin Cancer Res. 2018 Dec 15;24(24):6345-6354. (PMID: 30154226) N Engl J Med. 2018 Dec 13;379(24):2342-2350. (PMID: 30280658) Blood. 2016 Oct 6;128(14):1829-1833. (PMID: 27543436) Cancer Immunol Res. 2015 Sep;3(9):1030-41. (PMID: 26056145) N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797) Science. 2018 Oct 12;362(6411):. (PMID: 30309915) Immun Inflamm Dis. 2016 Aug 28;4(4):427-440. (PMID: 27980777) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) Cancer Immunol Res. 2019 Jan;7(1):136-149. (PMID: 30401677) Clin Cancer Res. 2019 Mar 1;25(5):1650-1663. (PMID: 30538110) J Thorac Oncol. 2017 Sep;12(9):e143-e144. (PMID: 28838715) J Immunol. 1990 Feb 15;144(4):1531-7. (PMID: 2303716) Cancer Res. 2013 Jun 15;73(12):3591-603. (PMID: 23633484) Cancer Res. 2017 Nov 1;77(21):e67-e70. (PMID: 29092943) Nature. 2015 Nov 12;527(7577):249-53. (PMID: 26503055) Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9. (PMID: 25071169) Cancer Res. 2016 Aug 15;76(16):4602-7. (PMID: 27474734) Cancer Immunol Res. 2017 Aug;5(8):676-684. (PMID: 28674082) Sci Transl Med. 2013 Oct 16;5(207):207ra144. (PMID: 24132639) J Exp Med. 2007 Aug 6;204(8):1787-801. (PMID: 17664294) Cancer Res Treat. 2020 Jan;52(1):149-166. (PMID: 31291716) Cancer Res. 2018 Dec 15;78(24):6717-6725. (PMID: 30498083) Lancet. 2019 Nov 23;394(10212):1929-1939. (PMID: 31590988) Lancet Oncol. 2019 Jul;20(7):948-960. (PMID: 31160251) N Engl J Med. 2019 Mar 21;380(12):1103-1115. (PMID: 30779531) J Immunother Cancer. 2019 Mar 20;7(1):80. (PMID: 30894212) Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909) J Clin Oncol. 2020 May 10;38(14):1505-1517. (PMID: 32150489) N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792) Invest New Drugs. 2019 Oct;37(5):876-889. (PMID: 30511201) Immunity. 2016 Feb 16;44(2):343-54. (PMID: 26872698) Cancer Immunol Immunother. 2016 Jun;65(6):753-63. (PMID: 27160390) J Thorac Oncol. 2020 Oct;15(10):1657-1669. (PMID: 32599071) Sci Rep. 2017 Apr 7;7(1):737. (PMID: 28389661) Eur J Immunol. 1993 Oct;23(10):2631-41. (PMID: 8405064) Nature. 2017 Aug 24;548(7668):471-475. (PMID: 28813415) Lancet Oncol. 2016 Nov;17(11):1497-1508. (PMID: 27745820) Nature. 2015 Apr 16;520(7547):373-7. (PMID: 25754329) Sci Immunol. 2017 May 5;2(11):. (PMID: 28763790) Cancer Res. 2012 Mar 1;72(5):1081-91. (PMID: 22237626) Cancer Res. 2013 Dec 15;73(24):7189-7198. (PMID: 24177180) Expert Opin Drug Discov. 2018 Nov;13(11):997-1003. (PMID: 30336706) J Thorac Oncol. 2017 Sep;12(9):e135-e136. (PMID: 28502722) Lancet Oncol. 2019 May;20(5):711-718. (PMID: 30922731) N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431) Science. 2019 Nov 22;366(6468):1013-1021. (PMID: 31699883) Front Immunol. 2018 Oct 09;9:2100. (PMID: 30356816) Lancet Oncol. 2018 May;19(5):603-615. (PMID: 29573941) N Engl J Med. 2019 Nov 21;381(21):2020-2031. (PMID: 31562796) Cancer Res. 1975 Sep;35(9):2434-9. (PMID: 1149045) J Exp Med. 1999 May 3;189(9):1363-72. (PMID: 10224276) JAMA Oncol. 2020 Oct 1;6(10):1563-1570. (PMID: 32852531) Cancer Discov. 2018 Oct;8(10):1250-1257. (PMID: 30154193) Cancer Res. 2012 Feb 15;72(4):917-27. (PMID: 22186141) Mol Cancer Ther. 2017 Apr;16(4):671-680. (PMID: 28138031) Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375) J Immunother Cancer. 2019 Oct 25;7(1):277. (PMID: 31653272) N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) Lancet Oncol. 2019 Jul;20(7):924-937. (PMID: 31122901) J Immunol. 2017 Jan 1;198(1):31-39. (PMID: 27994166) Nature. 2015 Apr 30;520(7549):692-6. (PMID: 25901682) Sci Transl Med. 2017 Apr 12;9(385):. (PMID: 28404865) Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759) J Immunol. 2009 Nov 15;183(10):6330-7. (PMID: 19841169) N Engl J Med. 2017 Oct 12;377(15):1409-1412. (PMID: 29020592) J Immunol. 2012 Dec 1;189(11):5147-54. (PMID: 23100512) Expert Opin Pharmacother. 2012 Jan;13(1):111-4. (PMID: 22149371) Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059) Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494) N Engl J Med. 2017 Jan 26;376(4):354-366. (PMID: 28121507) J Clin Oncol. 2015 Mar 20;33(9):983-91. (PMID: 25534375) Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990) Cancer Cell. 2017 Aug 14;32(2):253-267.e5. (PMID: 28810147) Nat Commun. 2017 Nov 24;8(1):1751. (PMID: 29170499) Sci Rep. 2019 Aug 7;9(1):11472. (PMID: 31391510) Cancer Discov. 2016 Feb;6(2):202-16. (PMID: 26645196) Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. (PMID: 28003307) Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. (PMID: 30042205) J Natl Compr Canc Netw. 2020 Jul;18(7):899-906. (PMID: 32634775) N Engl J Med. 2018 Dec 6;379(23):2220-2229. (PMID: 30280641) N Engl J Med. 2020 Sep 17;383(12):1139-1148. (PMID: 32877599) J Exp Med. 2013 Jul 1;210(7):1389-402. (PMID: 23752227) Nature. 2020 Nov;587(7832):121-125. (PMID: 33087933) J Clin Oncol. 2016 Nov 1;34(31):3740-3748. (PMID: 27458307) Oncoimmunology. 2012 Aug 1;1(5):609-617. (PMID: 22934253) Clin Cancer Res. 2016 Jan 15;22(2):436-47. (PMID: 26324743) Clin Cancer Res. 2019 Mar 1;25(5):1612-1623. (PMID: 30538109) Cancer Res. 2017 Dec 15;77(24):6795-6811. (PMID: 29247038) J Clin Oncol. 2018 Nov 10;36(32):3223-3230. (PMID: 30265610) Nat Commun. 2018 Jan 16;9(1):248. (PMID: 29339738) N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663) Cancer Res. 2016 Dec 1;76(23):6988-7000. (PMID: 27651308) Clin Cancer Res. 2019 Oct 1;25(19):5878-5889. (PMID: 31138587) Cancer Res. 1992 Mar 15;52(6):1399-405. (PMID: 1540948) Cancer Res. 2019 Jan 15;79(2):311-319. (PMID: 30482774) Cancer Immunol Res. 2019 Aug;7(8):1318-1331. (PMID: 31235619) J Clin Invest. 2019 Mar 1;129(3):1211-1228. (PMID: 30589644) Lancet Oncol. 2019 Oct;20(10):1370-1385. (PMID: 31427204) Nat Commun. 2019 Feb 22;10(1):899. (PMID: 30796212) Cancer Immunol Res. 2017 Sep;5(9):790-803. (PMID: 28775208) Leukemia. 2018 May;32(5):1094-1105. (PMID: 29487386) Cancer Cell. 2019 Nov 11;36(5):471-482. (PMID: 31715131) Blood. 2009 Jul 16;114(3):555-63. (PMID: 19465693) J Exp Med. 2015 Feb 9;212(2):139-48. (PMID: 25601652) Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2. (PMID: 25996827) J Immunol. 2005 Jan 15;174(2):688-95. (PMID: 15634887) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) Nat Med. 2018 Nov;24(11):1655-1661. (PMID: 30297911) J Immunother. 2020 Nov/Dec;43(9):291-298. (PMID: 32960847) Clin Cancer Res. 2016 Aug 15;22(16):4119-32. (PMID: 26964571) J Immunol. 2013 May 1;190(9):4899-909. (PMID: 23536636) Cell. 2015 Aug 27;162(5):974-86. (PMID: 26317466) FASEB J. 2018 Mar;32(3):1537-1549. (PMID: 29146734) PLoS One. 2014 Nov 05;9(11):e109080. (PMID: 25372844) Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. (PMID: 30540933) Nat Genet. 2009 May;41(5):544-52. (PMID: 19282848) |
| معلومات مُعتمدة: | P50 CA221703 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20210403 Date Completed: 20220218 Latest Revision: 20220218 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8178168 |
| DOI: | 10.1158/2159-8290.CD-20-1209 |
| PMID: | 33811048 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2159-8290 |
|---|---|
| DOI: | 10.1158/2159-8290.CD-20-1209 |